腸病毒71型能造成幼童嚴重神經病症，發展可能之治療藥物是目前首項要務。我們研究團隊篩選出一個具有抗腸病毒潛力的新藥物-DTriP-22， 為了鑑別此化合物的病毒分子標的，我們針對對DTriP-22具有抗藥性之病毒基因進行序列分析，發現若以離胺酸置換病毒核醣核酸聚合酶上第163個氨基酸位置上之精胺酸，將可改變病毒對DTriP-22的感受性。 DTriP-22可藉由降低在病毒感染期間病毒之正股或負股核醣核酸的累積量，進而抑制病毒複製。 而在體外聚合酶活性試驗中發現，DTriP-22可抑制腸病毒71型核醣核酸聚合酶之延長多聚尿嘧啶作用的活性，而非抑制其VPg尿苷酰化作用的活性。 這些研究結果顯示了就治療腸病毒71型而言，DTriP-22是一種新的核醣核酸聚合酶抑制劑。另外，我們進一步的實驗結果也發現DTriP-22具有抑制小核醣核酸病毒科中的其他型腸病毒的能力，顯示了此化合物之抗病毒效果的廣效性。 由我們的研究成果中顯示了DTriP-22具有進一步發展為臨床使用之抗病毒藥物的潛力。

Enterovirus 71 (EV71) has emerged as an important virulent neurotropic enterovirus in young children. DTriP-22 was found to be a novel and potent inhibitor of EV71. The molecular target of this compound was identified by analyzing DTriP-22-resistant viruses. A substitution of lysine for Arg163 in the EV71 3D polymerase rendered the virus drug-resistant. DTriP-22 exhibited the ability to inhibit viral replication by reducing viral RNA accumulation. The compound suppressed the accumulated levels of both viral positive- and negative-stranded RNA during virus infection. In vitro polymerase assay indicated that DTriP-22 inhibited the poly(U) elongation activity, but not VPg uridylylation activity, of EV71 polymerase. These findings demonstrate that a non-nucleoside analogue, DTriP-22, acts as a novel inhibitor of EV71 polymerase. DTriP-22 also exhibited a broad-spectrum of antiviral activity against other picornaviruses, which highlights its potential in the development of antiviral agents.

1. AbuBakar S., Chan Y.F. and Lam S.K. Outbreaks of enterovirus 71 infection. N Engl J Med 342(5):355-356, 2000.
2. AbuBakar S., Chee H.Y., Al-Kobaisi M.F., Xiaoshan J., Chua K.B. and Lam S.K. Identification of enterovirus 71 isolates from an outbreak of hand, foot and mouth disease (HFMD) with fatal cases of encephalomyelitis in Malaysia. Virus Res 61(1):1-9, 1999.
3. Aldabe R., Barco A. and Carrasco L. Membrane permeabilization by poliovirus proteins 2B and 2BC. J Biol Chem 271(38):23134-23137, 1996.
4. Alexander J.P., Jr., Baden L., Pallansch M.A. and Anderson L.J. Enterovirus 71 infections and neurologic disease--United States, 1977-1991. J Infect Dis 169(4):905-908, 1994.
5. Arita M., Nagata N., Iwata N., Ami Y., Suzaki Y., Mizuta K., Iwasaki T., Sata T., Wakita T. and Shimizu H. An attenuated strain of enterovirus 71 belonging to genotype a showed a broad spectrum of antigenicity with attenuated neurovirulence in cynomolgus monkeys. J Virol 81(17):9386-9395, 2007.
6. Arita M., Wakita T. and Shimizu H. Characterization of pharmacologically active compounds that inhibit poliovirus and enterovirus 71 infectivity. J Gen Virol 89(Pt 10):2518-2530, 2008.
7. Bedard K.M. and Semler B.L. Regulation of picornavirus gene expression. Microbes Infect 6(7):702-713, 2004.
8. Bienz K., Egger D. and Pasamontes L. Association of polioviral proteins of the P2 genomic region with the viral replication complex and virus-induced membrane synthesis as visualized by electron microscopic immunocytochemistry and autoradiography. Virology 160(1):220-226, 1987.
9. Brunner J.E., Nguyen J.H., Roehl H.H., Ho T.V., Swiderek K.M. and Semler B.L. Functional interaction of heterogeneous nuclear ribonucleoprotein C with poliovirus RNA synthesis initiation complexes. J Virol 79(6):3254-3266, 2005.
10. Chan K.P., Goh K.T., Chong C.Y., Teo E.S., Lau G. and Ling A.E. Epidemic hand, foot and mouth disease caused by human enterovirus 71, Singapore. Emerg Infect Dis 9(1):78-85, 2003.
11. Chang L.Y., Huang L.M., Gau S.S., Wu Y.Y., Hsia S.H., Fan T.Y., Lin K.L., Huang Y.C., Lu C.Y. and Lin T.Y. Neurodevelopment and cognition in children after enterovirus 71 infection. N Engl J Med 356(12):1226-1234, 2007.
12. Chang L.Y., Lin T.Y., Hsu K.H., Huang Y.C., Lin K.L., Hsueh C., Shih S.R., Ning H.C., Hwang M.S., Wang H.S. and Lee C.Y. Clinical features and risk factors of pulmonary oedema after enterovirus-71-related hand, foot, and mouth disease. Lancet 354(9191):1682-1686, 1999.
13. Chen H.F., Chang M.H., Chiang B.L. and Jeng S.T. Oral immunization of mice using transgenic tomato fruit expressing VP1 protein from enterovirus 71. Vaccine 24(15):2944-2951, 2006.
14. Chen T.C., Liu S.C., Huang P.N., Chang H.Y., Chern J.H. and Shih S.R. Antiviral activity of pyridyl imidazolidinones against enterovirus 71 variants. J Biomed Sci 15(3):291-300, 2008.
15. Chen T.C., Weng K.F., Chang S.C., Lin J.Y., Huang P.N. and Shih S.R. Development of antiviral agents for enteroviruses. J Antimicrob Chemother 62(6):1169-1173, 2008.
16. Chern J.H., Shia K.S., Hsu T.A., Tai C.L., Lee C.C., Lee Y.C., Chang C.S., Tseng S.N. and Shih S.R. Design, synthesis, and structure-activity relationships of pyrazolo[3,4-d]pyrimidines: a novel class of potent enterovirus inhibitors. Bioorg Med Chem Lett 14(10):2519-2525, 2004.
17. Chiu C.H., Chu C., He C.C. and Lin T.Y. Protection of neonatal mice from lethal enterovirus 71 infection by maternal immunization with attenuated Salmonella enterica serovar Typhimurium expressing VP1 of enterovirus 71. Microbes Infect 8(7):1671-1678, 2006.
18. Chung Y.C., Ho M.S., Wu J.C., Chen W.J., Huang J.H., Chou S.T. and Hu Y.C. Immunization with virus-like particles of enterovirus 71 elicits potent immune responses and protects mice against lethal challenge. Vaccine 26(15):1855-1862, 2008.
19. Di Marco S., Volpari C., Tomei L., Altamura S., Harper S., Narjes F., Koch U., Rowley M., De Francesco R., Migliaccio G. and Carfi A. Interdomain communication in hepatitis C virus polymerase abolished by small molecule inhibitors bound to a novel allosteric site. J Biol Chem 280(33):29765-29770, 2005.
20. Doedens J.R., Giddings T.H., Jr. and Kirkegaard K. Inhibition of endoplasmic reticulum-to-Golgi traffic by poliovirus protein 3A: genetic and ultrastructural analysis. J Virol 71(12):9054-9064, 1997.
21. Doedens J.R. and Kirkegaard K. Inhibition of cellular protein secretion by poliovirus proteins 2B and 3A. Embo J 14(5):894-907, 1995.
22. Flanegan J.B., Petterson R.F., Ambros V., Hewlett N.J. and Baltimore D. Covalent linkage of a protein to a defined nucleotide sequence at the 5'-terminus of virion and replicative intermediate RNAs of poliovirus. Proc Natl Acad Sci U S A 74(3):961-965, 1977.
23. Foo D.G., Alonso S., Phoon M.C., Ramachandran N.P., Chow V.T. and Poh C.L. Identification of neutralizing linear epitopes from the VP1 capsid protein of Enterovirus 71 using synthetic peptides. Virus Res 125(1):61-68, 2007.
24. Foo D.G., Macary P.A., Alonso S. and Poh C.L. Identification of human CD4 T-cell epitopes on the VP1 capsid protein of enterovirus 71. Viral Immunol 21(2):215-224, 2008.
25. Fujimoto T., Chikahira M., Yoshida S., Ebira H., Hasegawa A., Totsuka A. and Nishio O. Outbreak of central nervous system disease associated with hand, foot, and mouth disease in Japan during the summer of 2000: detection and molecular epidemiology of enterovirus 71. Microbiol Immunol 46(9):621-627, 2002.
26. Furuta Y., Takahashi K., Kuno-Maekawa M., Sangawa H., Uehara S., Kozaki K., Nomura N., Egawa H. and Shiraki K. Mechanism of action of T-705 against influenza virus. Antimicrob Agents Chemother 49(3):981-986, 2005.
27. Gerber K., Wimmer E. and Paul A.V. Biochemical and genetic studies of the initiation of human rhinovirus 2 RNA replication: identification of a cis-replicating element in the coding sequence of 2A(pro). J Virol 75(22):10979-10990, 2001.
28. Gohara D.W., Ha C.S., Kumar S., Ghosh B., Arnold J.J., Wisniewski T.J. and Cameron C.E. Production of "authentic" poliovirus RNA-dependent RNA polymerase (3D(pol)) by ubiquitin-protease-mediated cleavage in Escherichia coli. Protein Expr Purif 17(1):128-138, 1999.
29. Goodfellow I., Chaudhry Y., Richardson A., Meredith J., Almond J.W., Barclay W. and Evans D.J. Identification of a cis-acting replication element within the poliovirus coding region. J Virol 74(10):4590-4600, 2000.
30. Goris N., De Palma A., Toussaint J.F., Musch I., Neyts J. and De Clercq K. 2'-C-methylcytidine as a potent and selective inhibitor of the replication of foot-and-mouth disease virus. Antiviral Res 73(3):161-168, 2007.
31. Graci J.D., Too K., Smidansky E.D., Edathil J.P., Barr E.W., Harki D.A., Galarraga J.E., Bollinger J.M., Jr., Peterson B.R., Loakes D., Brown D.M. and Cameron C.E. Lethal mutagenesis of picornaviruses with N-6-modified purine nucleoside analogues. Antimicrob Agents Chemother 52(3):971-979, 2008.
32. Harki D.A., Graci J.D., Galarraga J.E., Chain W.J., Cameron C.E. and Peterson B.R. Synthesis and antiviral activity of 5-substituted cytidine analogues: identification of a potent inhibitor of viral RNA-dependent RNA polymerases. J Med Chem 49(21):6166-6169, 2006.
33. Herold J. and Andino R. Poliovirus RNA replication requires genome circularization through a protein-protein bridge. Mol Cell 7(3):581-591, 2001.
34. Ho M., Chen E.R., Hsu K.H., Twu S.J., Chen K.T., Tsai S.F., Wang J.R. and Shih S.R. An epidemic of enterovirus 71 infection in Taiwan. Taiwan Enterovirus Epidemic Working Group. N Engl J Med 341(13):929-935, 1999.
35. Jackson W.T., Giddings T.H., Jr., Taylor M.P., Mulinyawe S., Rabinovitch M., Kopito R.R. and Kirkegaard K. Subversion of cellular autophagosomal machinery by RNA viruses. PLoS Biol 3(5):e156, 2005.
36. Kehle J., Roth B., Metzger C., Pfitzner A. and Enders G. Molecular characterization of an Enterovirus 71 causing neurological disease in Germany. J Neurovirol 9(1):126-128, 2003.
37. Kishimoto C., Crumpacker C.S. and Abelmann W.H. Ribavirin treatment of murine coxsackievirus B3 myocarditis with analyses of lymphocyte subsets. J Am Coll Cardiol 12(5):1334-1341, 1988.
38. Knipe D.M., Howley P.M., Griffin D.E., Lamb R.A., Martin M.A., B; R. and Straus S.E. (Eds) Field's Virology, ed 5th. Lippincott Williams & Wilkins 2007.
39. Kuo C.J., Shie J.J., Fang J.M., Yen G.R., Hsu J.T., Liu H.G., Tseng S.N., Chang S.C., Lee C.Y., Shih S.R. and Liang P.H. Design, synthesis, and evaluation of 3C protease inhibitors as anti-enterovirus 71 agents. Bioorg Med Chem 16(15):7388-7398, 2008.
40. Lama J., Paul A.V., Harris K.S. and Wimmer E. Properties of purified recombinant poliovirus protein 3AB as substrate for viral proteinases and as co-factor for RNA polymerase 3Dpol. J Biol Chem 269(1):66-70, 1994.
41. Li Z.H., Li C.M., Ling P., Shen F.H., Chen S.H., Liu C.C., Yu C.K. and Chen S.H. Ribavirin reduces mortality in enterovirus 71-infected mice by decreasing viral replication. J Infect Dis 197(6):854-857, 2008.
42. Lin J.Y., Li M.L., Huang P.N., Chien K.Y., Horng J.T. and Shih S.R. Heterogeneous nuclear ribonuclear protein K interacts with the enterovirus 71 5' untranslated region and participates in virus replication. J Gen Virol 89(Pt 10):2540-2549, 2008.
43. Lin J.Y., Li M.L. and Shih S.R. Far upstream element binding protein 2 interacts with enterovirus 71 internal ribosomal entry site and negatively regulates viral translation. Nucleic Acids Res, 2008.
44. Lin T.Y., Twu S.J., Ho M.S., Chang L.Y. and Lee C.Y. Enterovirus 71 outbreaks, Taiwan: occurrence and recognition. Emerg Infect Dis 9(3):291-293, 2003.
45. Lobert P.E., Escriou N., Ruelle J. and Michiels T. A coding RNA sequence acts as a replication signal in cardioviruses. Proc Natl Acad Sci U S A 96(20):11560-11565, 1999.
46. Mason P.W., Bezborodova S.V. and Henry T.M. Identification and characterization of a cis-acting replication element (cre) adjacent to the internal ribosome entry site of foot-and-mouth disease virus. J Virol 76(19):9686-9694, 2002.
47. McKnight K.L. and Lemon S.M. The rhinovirus type 14 genome contains an internally located RNA structure that is required for viral replication. Rna 4(12):1569-1584, 1998.
48. McMinn P., Stratov I., Nagarajan L. and Davis S. Neurological manifestations of enterovirus 71 infection in children during an outbreak of hand, foot, and mouth disease in Western Australia. Clin Infect Dis 32(2):236-242, 2001.
49. McMinn P.C. An overview of the evolution of enterovirus 71 and its clinical and public health significance. FEMS Microbiol Rev 26(1):91-107, 2002.
50. Melnick J.L., Agol V.I., Bachrach H.L., Brown F., Cooper P.D., Fiers W., Gard S., Gear J.H., Ghendon Y., Kasza L., LaPlaca M., Mandel B., McGregor S., Mohanty S.B., Plummer G., Rueckert R.R., Schaffer F.L., Tagaya I., Tyrrell D.A., Voroshilova M. and Wenner H.A. Picornaviridae. Intervirology 4(5):303-316, 1974.
51. Parsley T.B., Towner J.S., Blyn L.B., Ehrenfeld E. and Semler B.L. Poly (rC) binding protein 2 forms a ternary complex with the 5'-terminal sequences of poliovirus RNA and the viral 3CD proteinase. Rna 3(10):1124-1134, 1997.
52. Paul A.V., Peters J., Mugavero J., Yin J., van Boom J.H. and Wimmer E. Biochemical and genetic studies of the VPg uridylylation reaction catalyzed by the RNA polymerase of poliovirus. J Virol 77(2):891-904, 2003.
53. Paul A.V., van Boom J.H., Filippov D. and Wimmer E. Protein-primed RNA synthesis by purified poliovirus RNA polymerase. Nature 393(6682):280-284, 1998.
54. Raboud J.M., Rae S., Vella S., Harrigan P.R., Bucciardini R., Fragola V., Ricciardulli D. and Montaner J.S. Meta-analysis of two randomized controlled trials comparing combined zidovudine and didanosine therapy with combined zidovudine, didanosine, and nevirapine therapy in patients with HIV. INCAS study team. J Acquir Immune Defic Syndr 22(3):260-266, 1999.
55. Richards O.C. and Ehrenfeld E. Poliovirus RNA replication. Curr Top Microbiol Immunol 161:89-119, 1990.
56. Richards O.C., Spagnolo J.F., Lyle J.M., Vleck S.E., Kuchta R.D. and Kirkegaard K. Intramolecular and intermolecular uridylylation by poliovirus RNA-dependent RNA polymerase. J Virol 80(15):7405-7415, 2006.
57. Sandoval I.V. and Carrasco L. Poliovirus infection and expression of the poliovirus protein 2B provoke the disassembly of the Golgi complex, the organelle target for the antipoliovirus drug Ro-090179. J Virol 71(6):4679-4693, 1997.
58. Schlegel A., Giddings T.H., Jr., Ladinsky M.S. and Kirkegaard K. Cellular origin and ultrastructure of membranes induced during poliovirus infection. J Virol 70(10):6576-6588, 1996.
59. Shih S.R., Tsai M.C., Tseng S.N., Won K.F., Shia K.S., Li W.T., Chern J.H., Chen G.W., Lee C.C., Lee Y.C., Peng K.C. and Chao Y.S. Mutation in enterovirus 71 capsid protein VP1 confers resistance to the inhibitory effects of pyridyl imidazolidinone. Antimicrob Agents Chemother 48(9):3523-3529, 2004.
60. Smee D.F., McKernan P.A., Nord L.D., Willis R.C., Petrie C.R., Riley T.M., Revankar G.R., Robins R.K. and Smith R.A. Novel pyrazolo[3,4-d]pyrimidine nucleoside analog with broad-spectrum antiviral activity. Antimicrob Agents Chemother 31(10):1535-1541, 1987.
61. Staszewski S., Morales-Ramirez J., Tashima K.T., Rachlis A., Skiest D., Stanford J., Stryker R., Johnson P., Labriola D.F., Farina D., Manion D.J. and Ruiz N.M. Efavirenz plus zidovudine and lamivudine, efavirenz plus indinavir, and indinavir plus zidovudine and lamivudine in the treatment of HIV-1 infection in adults. Study 006 Team. N Engl J Med 341(25):1865-1873, 1999.
62. Tedesco R., Shaw A.N., Bambal R., Chai D., Concha N.O., Darcy M.G., Dhanak D., Fitch D.M., Gates A., Gerhardt W.G., Halegoua D.L., Han C., Hofmann G.A., Johnston V.K., Kaura A.C., Liu N., Keenan R.M., Lin-Goerke J., Sarisky R.T., Wiggall K.J., Zimmerman M.N. and Duffy K.J. 3-(1,1-dioxo-2H-(1,2,4)-benzothiadiazin-3-yl)-4-hydroxy-2(1H)-quinolinones , potent inhibitors of hepatitis C virus RNA-dependent RNA polymerase. J Med Chem 49(3):971-983, 2006.
63. Thompson A.A. and Peersen O.B. Structural basis for proteolysis-dependent activation of the poliovirus RNA-dependent RNA polymerase. Embo J 23(17):3462-3471, 2004.
64. Tomei L., Altamura S., Bartholomew L., Biroccio A., Ceccacci A., Pacini L., Narjes F., Gennari N., Bisbocci M., Incitti I., Orsatti L., Harper S., Stansfield I., Rowley M., De Francesco R. and Migliaccio G. Mechanism of action and antiviral activity of benzimidazole-based allosteric inhibitors of the hepatitis C virus RNA-dependent RNA polymerase. J Virol 77(24):13225-13231, 2003.
65. Tomei L., Altamura S., Bartholomew L., Bisbocci M., Bailey C., Bosserman M., Cellucci A., Forte E., Incitti I., Orsatti L., Koch U., De Francesco R., Olsen D.B., Carroll S.S. and Migliaccio G. Characterization of the inhibition of hepatitis C virus RNA replication by nonnucleosides. J Virol 78(2):938-946, 2004.
66. Van Dyke T.A. and Flanegan J.B. Identification of poliovirus polypeptide P63 as a soluble RNA-dependent RNA polymerase. J Virol 35(3):732-740, 1980.
67. Verstrepen W.A., Kuhn S., Kockx M.M., Van De Vyvere M.E. and Mertens A.H. Rapid detection of enterovirus RNA in cerebrospinal fluid specimens with a novel single-tube real-time reverse transcription-PCR assay. J Clin Microbiol 39(11):4093-4096, 2001.
68. Wu C.N., Lin Y.C., Fann C., Liao N.S., Shih S.R. and Ho M.S. Protection against lethal enterovirus 71 infection in newborn mice by passive immunization with subunit VP1 vaccines and inactivated virus. Vaccine 20(5-6):895-904, 2001.
69. Wu S.C., Liu C.C. and Lian W.C. Optimization of microcarrier cell culture process for the inactivated enterovirus type 71 vaccine development. Vaccine 22(29-30):3858-3864, 2004.
70. Xiang W., Harris K.S., Alexander L. and Wimmer E. Interaction between the 5'-terminal cloverleaf and 3AB/3CDpro of poliovirus is essential for RNA replication. J Virol 69(6):3658-3667, 1995.
71. Yang Y., Yi M., Evans D.J., Simmonds P. and Lemon S.M. Identification of a conserved RNA replication element (cre) within the 3Dpol-coding sequence of hepatoviruses. J Virol 82(20):10118-10128, 2008.